Test-retest reliability and stability of the nicotine metabolite ratio among treatment-seeking smokers

Nicotine and Tobacco Research

Volumn 17, Issue 12, 2015, Pages 1505-1509

  Hamilton, Diana A ^a   Mahoney, Martin C ^a,b   Novalen, Maria ^c,d   Chenoweth, Meghan J ^c,d   Heitjan, Daniel F ^e   Lerman, Caryn ^f   Tyndale, Rachel F ^c,d   Hawk, Larry W ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; NICOTINE; BIOLOGICAL MARKER; HYDROXYCOTININE;

ADULT; ARTICLE; BEHAVIOR ASSESSMENT; BLOOD SAMPLING; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; MALE; MEASUREMENT; NICOTINE METABOLITE RATIO; OUTCOME ASSESSMENT; PHYSICAL PARAMETERS; PRIORITY JOURNAL; SCORING SYSTEM; SELF REPORT; SMOKING; STABILITY; TEST RETEST RELIABILITY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATIENT ATTITUDE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BIOMARKERS; COTININE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PATIENT ACCEPTANCE OF HEALTH CARE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973109293     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv031     Document Type: Article

References (36)

1. U.S. Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Printed with corrections, January 2014.
2. Fiore MC. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public health service report. Am J Prev Med. 2008;35(2):158-176.
3. Schlam TR, Baker TB. Interventions for tobacco smoking. Annu Rev Clin Psychol. 2013;9:675-702. doi:10.1146/annurev-clinpsy-050212-185602.
4. Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93(6):526-538. doi:10.1038/clpt.2013.57.
5. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997;282(3):1608-1614.
6. Nakajima M, Yamamoto T, Nunoya K, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther. 1996;277(2):1010-1015.
7. Chenoweth MJ, O'Loughlin J, Sylvestre MP, Tyndale RF. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenet Genomics. 2013;23(4):232-235. doi:10.1097/FPC.0b013e32835f834d.
8. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64-72. doi:10.1016/j.clpt.2004.02.011.
9. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004;149:615-626. doi:00008571-200409000-00006.
10. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011;103(17):1342-1346. doi:10.1093/jnci/djr237.
11. Benowitz NL, Hukkanen J, Jacob P III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;192:29-60. doi:10.1007/978-3-540-69248-5_2.
12. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P III. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003;5(5):621-624. doi:6DCURVYMPL1C6UQ5 [pii].
13. Chenoweth MJ, Novalen M, Hawk LW, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatmentseeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9);1773-1782. doi:10.1158/1055-9965.EPI-14-0427.
14. Derby KS, Cuthrell K, Caberto C, et al. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3526-3535. doi:10.1158/1055-9965.EPI-08-0424.
15. Kandel DB, Hu MC, Schaffran C, Udry JR, Benowitz NL. Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol. 2007;165(8):901-910. doi:10.1093/aje/kwm010.
16. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6):635-643. doi:10.1038/clpt.2009.19.
17. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600-608. doi:10.1016/j.clpt.2006.02.006.
18. Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008;84(3):320-325. doi:10.1038/clpt. 2008.57.
19. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6-11. doi:10.1016/j.pbb.2008.10.016.
20. Lerman C, Jepson C, Wileyto EP, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther. 2010;87(5):553-557. doi:10.1038/clpt. 2010.3.
21. Chen LS, Bloom AJ, Baker TB, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 2014;109(1):128-137. doi:10.1111/add.12353.
22. Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol. 2006;30(6):386-389.
23. Helen G St, Novalen M, Heitjan DF, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1105-1114. doi:10.1158/1055-9965.EPI-12-0236.
24. Mooney ME, Li ZZ, Murphy SE, Pentel PR, Le C, Hatsukami DK. Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1396-1400. doi:10.1158/1055-9965.EPI-08-0242.
25. Fleiss JL. The Design and Analysis of Clinical Experiments. New York, NY: Wiley; 1986.
26. Skinner HA. Correlational methods in clincial research. In: Bellack AS, Hersen M, eds. Research Methods in Clinical Psychology. New York, NY: Pergamon Press; 1984.
27. Schnoll RA, George TP, Hawk L, Cinciripini P, Wileyto P, Tyndale RF. The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology (Berl). 2014;231(12):2515-2523. doi:10.1007/s00213-013-3421-1.
28. Cunningham JA, Selby PL. Future intentions regarding quitting and reducing cigarette use in a representative sample of Canadian daily smokers: implications for public health initiatives. Int J Environ Res Public Health. 2010;7(7):2896-2902. doi:10.3390/ijerph7072896.
29. Hughes JR, Solomon LJ, Livingston AE, Callas PW, Peters EN. A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit. Drug Alcohol Depend. 2010;111 (1-2):105-113. doi:10.1016/j.drugalcdep.2010.04.007.
30. Peters EN, Hughes JR. The day-to-day process of stopping or reducing smoking: a prospective study of self-changers. Nicotine Tob Res. 2009;11(9):1083-1092. doi:10.1093/ntr/ntp105.
31. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002;7(1):19-40.
32. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420-428.
33. Weir JP. Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res. 2005;19(1):231-240.
34. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. New York, NY: Wiley; 2003.
35. Shiffman S, Dunbar MS, Benowitz NL. A comparison of nicotine biomarkers and smoking patterns in daily and nondaily smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1264-1272. doi:10.1158/1055-9965.EPI-13-1014.
36. Helen G St, Jacob P III, Benowitz NL. Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob Res. 2013;15(11):1939-1942. doi:10.1093/ntr/ntt065.